Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2017 16:05 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference

COPENHAGEN, Denmark, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
November 16, 2017 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Third Quarter 2017 Financial Results

- Phase 3 Program for TransCon Growth Hormone Advances and TransCon PTH Enters the Clinic - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, Nov. 16, 2017 (GLOBE...
November 02, 2017 18:45 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Third Quarter 2017 Financial Results Conference Call on November 16

COPENHAGEN, Denmark, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
October 31, 2017 08:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in Two Upcoming Investor Conferences

COPENHAGEN, Denmark, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
September 27, 2017 00:16 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering...
September 26, 2017 16:17 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public...
September 26, 2017 08:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

COPENHAGEN, Denmark, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
September 05, 2017 16:25 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Presentations on Rare Disease Endocrinology Pipeline at Upcoming Medical Conferences

COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...
August 18, 2017 07:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Second Quarter 2017 Financial Results

- Clinical Pipeline Expands to Include TransCon PTH while Phase 3 Program for TransCon Growth Hormone Advances - - Conference Call Today at 8:00 a.m. Eastern Time - COPENHAGEN, Denmark, Aug. ...
August 08, 2017 08:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Upcoming Investor Presentations

COPENHAGEN, Denmark, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...

keyboard_arrow_left Previous Page